ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00882557
Recruitment Status : Completed
First Posted : April 16, 2009
Results First Posted : October 25, 2011
Last Update Posted : February 6, 2018
Sponsor:
Information provided by (Responsible Party):
Cubist Pharmaceuticals LLC

Brief Summary:
The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.

Condition or disease Intervention/treatment Phase
End-stage Renal Disease Renal Failure Chronic Requiring Hemodialysis Drug: daptomycin Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis
Actual Study Start Date : April 29, 2009
Actual Primary Completion Date : July 17, 2009
Actual Study Completion Date : July 17, 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
Drug Information available for: Daptomycin
U.S. FDA Resources

Arm Intervention/treatment
Experimental: A
9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.
Drug: daptomycin
intradialytic: 9 mg/kg during the last 30 minutes of dialysis
Other Name: Cubicin
Experimental: B
Post dialysis dosing
Drug: daptomycin
6 mg/kg administered after a hemodialysis session
Other Name: Cubicin



Primary Outcome Measures :
  1. Evaluation of Area Under the Curve From Time 0 to Infinity [ Time Frame: Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion) ]
    Area under the plasma concentration versus time curve from time 0 to infinity for daptomycin doses


Secondary Outcome Measures :
  1. Treatment-emergent Adverse Events [ Time Frame: Up to 9 days after the last dose of study drug administration (Day 13 to Day 17 for those dosed on Day 8 and Day 20 to Day 24 for those dosed on Day 15). ]
    Safety was monitored throughout the study, including observation and reports of AEs as well as changes in physical findings, vital signs, ECGs, and laboratory tests.


Other Outcome Measures:
  1. Maximum Plasma Concentration [ Time Frame: Within 30 minutes prior to the start of the infusion, mid-infusion, and end of the infusion; at 1, 2, 4, 6, 9, 24, and 48 hours after the end of the infusion; and just prior to the next hemodialysis session (i.e., 68 hours post-infusion) ]
    Maximum plasma concentration over the entire sampling phase directly obtained from the experimental plasma concentration time data, without interpolation.

  2. Time to Maximum Concentration [ Time Frame: Up to 68 hours post dose ]
    Sampling time at which maximum plasma concentration occurred, obtained directly from the experimental plasma concentration time data, without interpolation.

  3. Half-life [ Time Frame: Up to 68 hours post dose ]
    Apparent terminal half-life.

  4. Clearance of Daptomycin [ Time Frame: Up to 68 hours post dose ]
    Plasma clearance is dose (µg) divided by area under the concentration versus time curve from time 0 to last quantifiable concentration time.

  5. Volume of Distribution [ Time Frame: Up to 68 hours post dose ]
    Volume of distribution at steady state (mL) calculated as the product of clearance and mean residence time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent prior to any study-related procedure not part of normal medical care;
  • Male or female ≥ 18 years of age;
  • If female of childbearing potential; willing to practice reliable birth control measures during study treatment and for at least 28 days after study completion, not lactating or pregnant, and has a documented negative pregnancy test result within 24 hours prior to study medication administration;
  • End-stage renal disease on stable (for at least 2 weeks) hemodialysis regimen, three times weekly using high-flux membranes;
  • Functioning hemodialysis access (for example, graft or fistula);
  • Considered to be in appropriate health for study entry by the Investigator (for example, no acute, debilitating medical problems) and appropriate candidate for completing study treatment;
  • If taking concomitant medications, subject must be on a relatively stable dose for at least two weeks prior to study drug administration.

Exclusion Criteria:

  • Received an investigational drug (including experimental biologic agents) within 30 days of study drug administration;
  • Has received any dose of daptomycin within 7 days prior to study drug administration;
  • Known to be allergic or intolerant to daptomycin;
  • Evidence of active ongoing infection;
  • Known human immunodeficiency virus (HIV) infection with CD4 count ≤ 200 cells/mm3;
  • Active illicit drug use or alcohol abuse;
  • Myocardial infarction within last 6 months;
  • Subject with a history of muscular disease (for example, polymyositis, muscular dystrophy);
  • Subject with a history of neurological disease (for example, Guillain Barré, multiple sclerosis), except stroke > 6 months prior to study entry;
  • Intramuscular injection within 7 days of study drug administration;
  • Body mass index (BMI) ≤ 18.5 or ≥ 40 kg/m2 (BMI = weight [kg]/height [m2]);
  • WBC ≥ 12, 000 cells/mm3 or ≤ 2500 cells/ mm3;
  • Neutropenic subject with absolute neutrophil count ≤ 500 cells/mm3;
  • Baseline CPK values ≥ 3X ULN (upper limit of normal);
  • Alanine aminotransferase (ALT) > 5XULN;
  • Aspartate aminotransferase (AST) > 5XULN;
  • Hemoglobin ≤ 9 gm/dL;
  • Is considered unlikely to comply with study procedures or to return for scheduled post-treatment evaluations;
  • History of rhabdomyolysis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00882557


Locations
United States, California
West Coast Clinical Trials
Cypress, California, United States, 90630
United States, Minnesota
DaVita Clinical Research
Minneapolis, Minnesota, United States, 55404
Sponsors and Collaborators
Cubist Pharmaceuticals LLC
Investigators
Study Director: Alistair Wheeler, MD, MFPM Cubist Pharmaceuticals LLC

Responsible Party: Cubist Pharmaceuticals LLC
ClinicalTrials.gov Identifier: NCT00882557     History of Changes
Other Study ID Numbers: 3009-027
DAP-RENID-08-06 ( Other Identifier: Cubist Study Number )
First Posted: April 16, 2009    Key Record Dates
Results First Posted: October 25, 2011
Last Update Posted: February 6, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php

URL: http://

Keywords provided by Cubist Pharmaceuticals LLC:
End-stage renal disease
hemodialysis
chronic renal failure

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
Urologic Diseases
Renal Insufficiency, Chronic
Daptomycin
Anti-Bacterial Agents
Anti-Infective Agents